Navigation Links
Cytochroma opens U.S. headquarters in Illinois

MARKHAM, ON, April 29 /PRNewswire/ - Cytochroma today announced the opening of its U.S. headquarters in Bannockburn, Illinois, located in the greater Chicago area. The site will serve as the Company's base for U.S. commercial activities and for the expansion of its North American clinical and regulatory operations.

The expansion into the U.S. will ensure that appropriate resources are available to support the Company's numerous planned clinical programs as well as subsequent U.S. product launches. Members of Cytochroma's current management team to be based in the Bannockburn office include Joel Z. Melnick, M.D., Vice President of Clinical and Regulatory Affairs and Eric J. Messner, MBA, Vice President of Commercial Operations. The Company will retain and continue growing its existing corporate headquarters in Markham.

Charles W. Bishop, PhD., President and CEO, commented, "This is an ideal time for Cytochroma to establish U.S. operations, as we move our lead programs into mid- to late-stage clinical trials and execute plans to develop our commercial infrastructure. The Chicago area is a prime location for Cytochroma, given the presence of a number of world-class pharmaceutical and healthcare companies focused on the chronic kidney disease market and the strong intellectual capital present in the region."

Cytochroma has a diverse portfolio of Vitamin D-based therapeutics designed to treat disorders related to abnormal or insufficient Vitamin D metabolism in chronic kidney disease (CKD) patients. These new products will address target markets that are expected to grow significantly, reaching more than $1.2 billion annually by 2010 in North America alone. Cytochroma has three lead product candidates in development for CKD patients: CTA018 and CTAP201 are being developed for the treatment of secondary hyperparathyroidism (SHPT), while CTAP101 is being developed for the treatment of Vitamin D insufficiency.

About Chronic Kidney Disease

According to the National Kidney Foundation (NKF), more than nine million North American patients suffer from moderate CKD (Stages 3 and 4) to severe CKD (Stage 5). Stages 3 and 4 are characterized by progressively decreasing kidney function as measured by glomerular filtration rate. In Stage 5, kidney function is altogether absent and patients require regular dialysis or kidney transplant for survival. An estimated 70-90% of CKD patients have Vitamin D insufficiency, which can lead to SHPT and resultant debilitating bone diseases. Mounting evidence continues to link Vitamin D insufficiency with CKD progression and increased morbidity and mortality in CKD patients. CKD is most frequently caused by diabetes or hypertension, both of which are consequences of a growing obesity epidemic in countries worldwide.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of Vitamin D insufficiency and SHPT associated with CKD. The Company's Vitamin D-based therapeutics are designed to safely and effectively treat pre-dialysis and dialysis CKD patients. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia. For more information, please visit

SOURCE Cytochroma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
2. Cartesian Gridspeed Opens Subsidiary Operation in North America
3. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
4. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
5. Kaiser Permanente Colorado Opens Center for Health Dissemination and Implementation Research
6. ThalesNano Inc. Opens Own Representation in the United Kingdom and has New Distribution Agreements for Europe and India
7. The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus
8. MichBio Expo Opens in Lansing Next Week
9. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
10. NicOx Opens U.S. Headquarters in New Jersey
11. Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice
Post Your Comments:
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is ... it is bound to proteins, copper is also toxic to cells. With a ... Polytechnic Institute (WPI) will conduct a systematic study of copper in the bacteria ...
(Date:11/24/2015)... ... , ... This fall, global software solutions leader SAP and AdVenture Capital brought ... pitch their BIG ideas to improve health and wellness in their schools. , Now, ... the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):